Bxtaccelyon Limited

Active08252168 Private limited company

Incorporated: 15 October 2012 (14 years)
Previously known as: Accelyon Limited (until 6 March 2014)
Industry: Specialists medical practice activities (86220)
Directors: Malcolm Keith Hughes
Saheed Rashid
Owned by: Seed Bidco Limited
Accounts type: Full
Region: South East
Address: The Coach House
Grenville Court Britwell Road
Burnham
Slough
SL1 8DF

Website & contact details

Website: bxta.com

Filing status

Accounts due: 31 March 2027
Last accounts: 30 June 2025
Conf. stmt due: 15 June 2027
Last conf. stmt: 1 June 2026

Charges

Total: 3
Outstanding: 0
Part satisfied: 0
Satisfied: 3

Officers 2 active

Officer details are public data from the Companies House register.

Hughes, Malcolm Keith

Director · Appointed 17 April 2013

Also at Seed Bidco Limited, Seed Newco Limited · more companies

British

Born July 1954 (72)

Rashid, Saheed

Director · Appointed 15 October 2012

Also at Seed Bidco Limited, Seed Newco Limited

British

Born March 1962 (64)

Officer history (2 former)

17 April 2013

Appointed Hughes, Malcolm Keith as Director

17 April 2013

Resigned Rashid, Louise as Director

15 October 2012

Appointed Rashid, Saheed as Director

15 October 2012

Appointed Kahan, Barbara as Director

15 October 2012

Resigned Kahan, Barbara as Director

15 October 2012

Appointed Rashid, Louise as Director

Ownership 1 active

People and entities with significant control, from the Companies House PSC register

Seed Bidco Limited

Corporate entity · Notified 6 April 2016

Owns 75–100% of shares

Holds 75–100% of voting rights

Private Company Limited By Shares

Reg. no. 08544735

Holdings 1

Companies where Bxtaccelyon Limited is registered as a person with significant control

Bxta Nanotherapy Ltd

Owns 75–100% of shares

Active

Group structure 4 shown

Ownership group derived from the Companies House PSC register

Bxtaccelyon Group Limited

Seed Newco Limited Owns 75–100% of shares

Seed Bidco Limited Owns 75–100% of shares

Bxtaccelyon Limited This company Owns 75–100% of shares

Financials

Balance sheet as at 30 June 2025 · full accounts

Net Assets: £18,111,395
Cash: £6,940,061
Turnover: £14,836,942
Profit Before Tax: £3,611,749
Employees: 19

Debt Ratio: 13%
Current Ratio: 6.9x
Profit Margin: 24%
Return on Equity: 14%

Trend

Turnover

Balance sheet detail

	2025	2024	2023	2022	2021	2020	2019
Fixed Assets	£2,636,863	£2,439,563	£1,474,635	£1,114,369	£1,319,872	£1,496,774	£492,664
Current Assets	£18,208,253	£15,844,295	£13,361,453	£10,265,276	£6,345,467	£3,126,859	£1,662,907
Debtors	£9,944,774	£9,412,261	£6,035,528	£1,942,921	£1,076,143	£591,264	£746,397
Cash	£6,940,061	£4,789,627	£6,140,563	£8,259,180	£4,806,828	£2,375,991	£861,484
Creditors (< 1 year)	£2,638,763	£2,688,064		£2,738,840	£2,458,256	£2,039,166	£1,985,893
Net Current Assets	£15,569,490	£13,156,231	£11,188,361	£7,526,436	£3,887,211	£1,087,693	(£322,986)
Net Assets	£18,111,395	£15,479,361	£12,512,224
Shareholder Funds	£18,111,395	£15,479,361	£12,512,224	£8,470,597	£4,947,244	£2,352,363	(£30,322)

Turnover	£14,836,942	£14,837,241	£14,734,491
Cost of Sales	£7,484,841	£7,682,904	£7,355,822
Gross Profit	£7,352,101	£7,154,337	£7,378,669
Admin Expenses	£3,822,236	£3,607,624	£2,399,586
Staff Costs	£1,443,047	£1,160,849	£970,073
Operating Profit	£3,529,865	£3,546,713
Profit Before Tax	£3,611,749	£3,582,977	£5,021,037
Tax	£1,000,585	£640,311	£998,840
Profit for Period	£2,611,164	£2,942,666	£4,022,197

What Bxtaccelyon say about themselves

“With over 100 years’ combined experience, BXTA brings new focus and unrivalled commitment to the diagnosis and treatment of prostate cancer.”

— from bxta.com

Filings 48

Date	Description	Made Up To
12 June 2026	Satisfaction of a charge in full
12 June 2026	Satisfaction of a charge in full
12 June 2026	Satisfaction of a charge in full
9 June 2026	Confirmation statement with no updates	1 June 2026
6 February 2026	Full accounts	30 June 2025